A female infant, born to first cousin parents, lapsed into coma with severe metabolic acidosis on day three of life. The gas chromatographic/mass spectrometric urinary organic acid profile showed marked elevation of the leucine metabolites 3-hydroxy-3-methylglutaric, 3-methylglutaconic, 3-methylglutaric and 3-hydroxy-isovaleric acids. Less than 5% of the normal activity of the enzyme 3-hydroxy-3-methylglutaryl CoA lyase was detected in cultured skin fibroblasts. The patient's total and free carnitine was initially low but rose to normal levels after placing her on nL-carnitine (100 mg kg -I d-0. On a diet providing 87mgkg-ld -a of leucine and only 25% of total calories as fat and 2 gkg -a d -~ protein, the concentration of the urinary organic acids fell markedly. She is now 15 months old with normal growth and development. This regimen appears effective in the early treatment of 3-hydroxy-3-methylglutaric aciduria.
only small elevations in serum organic acids may be observed . Wysocki and colleagues (1976) and Wysocki and Hahnel (1976a; documented the deficiency of the 3-hydroxy-3-methylglutaryl CoA lyase in skin fibroblasts and leukocytes. The placenta and liver were also found to have little enzymatic activity in other affected children Schutgens et al., 1979; Robinson et al., 1980; Norman et al., 1982) . Consanguinity and intermediate parental enzyme levels were reported in several cases (Gibson et al., 1982; Greene et at'., 1984; Wilson et al., 1984) , thus providing evidence for autosomal recessive inheritance.
We report another infant with this condition who responded to a low fat, low protein diet, supplemented with carnitine.
CASE REPORT
The 1J-month-old girl presented on day three of life with gasping, duskiness and vomiting. On admission she had shallow, slow respirations, hypothermia (34.4°C), abdominal distention and a palpable liver (3 cm below the costal margin). She showed easy bruising at venipuncture sites. She was the product of a full term pregnancy and uncomplicated vaginal delivery to a 22-year-old gravida 2 parity 1 healthy Arabic woman. The parents are first cousins. The birthweight was 3.54 kg and Apgar scores were normal, 9 and 9 at 1 and 5 min respectively. At the time of admission the patient was intubated and put on a ventilator. On the second day she had a fit for which anticonvulsant therapy was initiated. Laboratory investigations included arterial blood gases which showed metabolic acidosis (pH7.2, pCO233, bicarbonate 13), requiring intravenous infusion with sodium bicarbonate. The blood glucose was normal and urinalysis demonstrated no ketonuria. Total and direct bilirubin were 8.9 and 0.9mgdL -1. The transaminases (SGOT, SGPT) and LDH were elevated (640, 262 and 2290 IU L -1 respectively). The prothrombin time was increased (26.7/22s) and fibrinogen was decreased (117 mg dL-1). Blood ammonia (233 pmol L-1), lactic acid (6.1 meq L-1) and pyruvic acid (2.7 mg dL -1) were elevated. No evidence of infection was obtained and EEG and cranial ultrasound examinations were normal. Because of the history of consanguinity and the finding of non-ketotic metabolic acidosis in a comatose baby, a metabolic disease was suspected. Urinary gas chromatography/mass spectrometry analysis showed massive elevation of organic acids characteristic of 3-hydroxy-3-methylglutaric aciduria (Table 1 ). The patient had initial plasma total and free carnitine levels of 28.9 and 7.8/~molL -1. She was put on DL-carnitine, 100 mg kg -1 d -~, and a 2 g kg -1 d -~ protein diet. Her carnitine concentrations rose to 62.6 and 42.7 pmol L -1 (total and free) after four days of therapy. The discharge formula provided a daily intake of 2 g kg -~ of protein, 87 mg kg -~ of leucine, 25% of total caloric intake as fat and 100 mgkg -~ DL-carnitine.
METHODS
The urinary organic acids were profiled by gas chromatography/mass spectrometry as the trimethylsilyl derivatives after solvent extraction (Goodman and Markey, 1981) . Selected ion monitoring mass spectrometry on an HP 5995B GC/MS using a Supelco SPB-1 60 m 'mega bore' column was used for quantification of the urinary organic acids. The method of standard additions to a normal urine was employed to obtain a working curve for each acid which was quantified.
HMG-CoA lyase activity was determined by two methods using lysates of cultured skin fibroblasts from the patient. The direct method utilized [~4C]-HMGCoA as a substrate using a modification of the method of Gibson and colleagues (1982) , while the indirect method can detect blocks at three steps in the leucine pathway. In this coupled assay the combined activities of 3-methylcrotonyl-CoA carboxylase (EC 6.4.1.4), 3-methylglutaconyl-CoA hydratase (EC 4.2.1.18) and 3-hydroxy-3-methylglutaryl-CoA lyase (EC 4.1.3.4) are determined. 3-methylcrotonyl-CoA and NaH14CO3 are used as substrates and exogenous 3-hydroxybutyrate dehydrogenase (EC 1.1.1.30), NADH and ATP are added. 1-[14C]-acetoacetic acid is converted to the stable 1-[a4C]-3-hydroxybutyric acid. The free acids are separated and quantified by reverse phase HPLC after hydrolysis of the coenzyme A esters. Table 1 shows a marked elevation of 3-hydrox3"-3-methylglutaric, 3-methylglutaconic, 3-methylgtutaric and 3-hydroxyisovaleric acid excretion in the urine. 3-hydroxy-3-methylglutaric acid was the major metabolite. Although newborns may normally excrete some 3-hydroxy-3-methylglutaric acid in their urine (Lippe et al., 1982), the urinary excretion of other leucine metabolites and documentation of the enzyme deficiency established the diagnosis of 3-hydroxy-3-methylglutaric aciduria. Less than 5% of the activity of 3-hydroxy-3-methylglutaryl-CoA lyase was detected in lysates of cultured skin fibroblasts (Table 2) , and in the coupled assay there was no production of 1-[14C]-3-hydroxybutyric acid, thereby localizing the defect to the final step in leucine degradation. The patient's initial plasma leucine concentration was 90/xmolL -1 (normal: 77+21), and she required bicarbonate maintenance for the acidosis. Restriction of her leucine intake to 87 mg kg -x d-i resulted in a decrease in the abnormal urinary organic acid excretion while preserving an acceptable plasma leucine concentration.
RESULTS AND DISCUSSION
Carnitine deficiency was found in this patient. Both total and free plasma carnitine 4, 3,6, 4.7 rose from 28.9 and 7.8/zmol L-a to 62.6 and 42.7 tzmol L-1, four days after placing her on OL-carnitine (100 mg kg -i d-l). This confirms the previous findings in two patients with 3-hydroxy-3-methylglutaric aciduria reported by Chalmers and colleagues (1984a; 1984b) . Secondary carnitine deficiency has been reported by other investigators associated with a number of inborn errors of metabolism. In 3-hydroxy-3-methylglutaric aciduria, acetoacetic acid is not formed and an increased intramitochondrial acyl CoA/CoASH results. Acyl CoA moieties will be conjugated with carnitine to form acyl carnitines which are excreted in the urine causing secondary carnitine deficiency (Chalmers et al., 1984a; 1984b) . Symptoms of carnitine deficiency may overlap with those of Reye's syndrome and 3-hydroxy-3-methylglutaric aciduria. These include vomiting, fatigue, muscle weakness and altered level of consciousness. Hepatomegaly, hypoglycaemia and elevated liver enzymes are also seen. Correction of carnitine deficiency may therefore result in clinical improvement.
Restriction of fat intake in 3-hydroxy-3-methylglutaric aciduria was reported in two patients by Berry and colleagues (1981) . This should decrease the amount of acetoacetate formed, minimizing the demand on acetyl-CoA and thus reducing the inhibition of pyruvate carboxylase which controls gluconeogenesis through phosphoenolpyruvate. This patient showed marked clinical improvement after the adjustment of her diet to limit the intake of total protein (2 g kg -1 d-1), fat (25 % of total calories) and leucine (87 mg kg -~ d-~), along with carnitine supplementation.
She is .currently 15 months old and has demonstrated normal growth and development for her age with only one episode of acute acidosis in the first year of life. This was readily controlled with intravenous bicarbonate.
